Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Xeloda in advanced hepatocellular carcinoma with Child-Pugh B liver function
2013-001483-39Phase 2Active
- Sponsor
- Istituto Oncologico Veneto
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in hepatocellular carcinoma (HCC), sponsored by Istituto Oncologico Veneto. Primary endpoint: Objective response rate. Started Jan 2014; status: active.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2013-001483-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001483-39.